CEO Message | Takeda Annual Integrated Report 2026

Message from our President and CEO

Dear Stakeholders,

Fiscal year 2025 (FY2025) was a critical year for Takeda as we had outstanding progress on our pipeline while delivering solid financial performance, setting us up for a future of accelerating growth.

As the newly appointed CEO of Takeda, it is a privilege to share our 2026 Annual Integrated Report, reflecting on achievements of FY2025 and looking ahead to what’s next for Takeda and our stakeholders. To continuously and sustainably drive better health for patients through our discovery and delivery of life-transforming medicines, we must uphold the highest standards of ethics and governance, support and develop our people, appropriately manage our environmental impacts and maintain financial discipline. These commitments – summarized in this report – strengthen our resilience and ability to create long‑term value. This year’s report also provides a view into our efforts to strengthen our competitiveness and build growth momentum. Later this fiscal year, I will outline my longer-term ambition and strategy for growth acceleration in greater detail, which will be rooted in the progress and achievements outlined in this report.

I want to acknowledge our previous CEO, Christophe Weber, whose deliberate and bold choices delivered the global scale and innovative pipeline we are now building upon.

During 2025, we saw some of the results of those efforts as we delivered positive Phase 3 data for rusfertide, oveporexton and zasocitinib. We completed regulatory filings for oveporexton in the U.S., Japan and China, and for rusfertide in the U.S.; zasocitinib will be filed in FY2026.

We continued to build and advance our robust late-stage pipeline, including the addition of two next-generation investigational oncology medicines from our strategic partnership with Innovent Biologics, which have the potential to address critical treatment gaps for patients with a range of solid tumors. In addition, we initiated Phase 3 studies for elritercept and mezagitamab, further strengthening the depth of our late-stage pipeline.

From our labs to the field, we further invested in advanced technology and tools, from artificial intelligence (AI) to automation, that strengthen our ability to deliver innovative medicines with greater speed and efficiency. I am proud of how our teams delivered meaningful progress for the patients and communities we serve amidst a complex and constantly evolving global landscape marked by geopolitical shifts, regulatory changes and economic uncertainty.

In January, as part of the final phase of the CEO transition, I established my leadership team and redesigned the organization to bring leadership and teams closer to patients and customers. I also introduced efforts to standardize ways of working and simplify processes to create further agility, and accelerate adoption of advanced technologies, especially AI.

These changes are crucial as we enter our next era. We are building a growth engine through investment and transformation that has the potential to fundamentally reshape the future for the company, expanding the impact on patients’ lives, supporting our talented employees and delivering long-term value to shareholders.

We are operating with two horizons: Horizon One strengthens our competitiveness and builds a growth engine through investment and transformation near-term. Horizon Two delivers accelerated growth in the mid-to-long term as we scale for multiple waves of launches, which will expand our patient impact and create long-term shareholder value.

I want to acknowledge our previous CEO, Christophe Weber, whose deliberate and bold choices delivered the global scale and innovative pipeline we are now building upon. During 2025, we saw some of the results of those efforts as we delivered positive Phase 3 data for rusfertide, oveporexton and zasocitinib. We completed regulatory filings for oveporexton in the U.S., Japan and China, and for rusfertide in the U.S.; zasocitinib will be filed in FY2026. We continued to build and advance our robust late-stage pipeline, including the addition of two next-generation investigational oncology medicines from our strategic partnership with Innovent Biologics, which have the potential to address critical treatment gaps for patients with a range of solid tumors. In addition, we initiated Phase 3 studies for elritercept and mezagitamab, further strengthening the depth of our late-stage pipeline. From our labs to the field, we further invested in advanced technology and tools, from artificial intelligence (AI) to automation, that strengthen our ability to deliver innovative medicines with greater speed and efficiency. I am proud of how our teams delivered meaningful progress for the patients and communities we serve amidst a complex and constantly evolving global landscape marked by geopolitical shifts, regulatory changes and economic uncertainty. In January, as part of the final phase of the CEO transition, I established my leadership team and redesigned the organization to bring leadership and teams closer to patients and customers. I also introduced efforts to standardize ways of working and simplify processes to create further agility, and accelerate adoption of advanced technologies, especially AI. These changes are crucial as we enter our next era. We are building a growth engine through investment and transformation that has the potential to fundamentally reshape the future for the company, expanding the impact on patients’ lives, supporting our talented employees and delivering long-term value to shareholders. We are operating with two horizons: **Horizon One** strengthens our competitiveness and builds a growth engine through investment and transformation near-term. **Horizon Two** delivers accelerated growth in the mid-to-long term as we scale for multiple waves of launches, which will expand our patient impact and create long-term shareholder value.

In this current horizon we are committed to:

As we invest in critical near-term launches, our pipeline and technology, we remain disciplined in managing our financial commitments. We are building an engine to unlock the next era of growth for Takeda, shifting from our maturing portfolio to a new cohort of blockbuster brands. Across both horizons, we will remain anchored in our purpose and values as we act with urgency to deliver transformative medicines to patients. You can read more about how we’re charting a successful future in my full Shareholder Letter.

Thank you for your continued support as we embark on Takeda’s next era and deliver on our generational promise to boldly reinvent for a healthier world.

Sincerely,

Julie Kim signature

Julie Kim
President and Chief Executive Officer